Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir

Currently, interferon alpha and nucleos(t)ide analogues (NAs) are clinically available to treat hepatitis B virus (HBV) infection. Several NAs, including lamivudine (LMV), adefovir (ADV), entecavir (ETV) and tenofovir (TDF or TAF) have been approved and administered to chronic hepatitis B (CHB) patients. NAs inhibit HBV DNA synthesis by targeting the reverse transcriptase (RT) domain of HBV polymerase. Several mutations in the RT domain which lead to drug resistance against NAs have been reported, even for TDF and TAF which are highly potent with very low resistance rate. Besifovir (BFV) is a new antiviral dGMP analogue able to be used as a new NA drug for the control of CHB infection. Drug resistance to BFV is not well known due to its shorter duration of clinical use. Recently, we reported that rtL180M (M) and rtM204V (V) mutations, already resistant to LMV, are associated with BFV resistance. However, the susceptibility to BFV of previously known HBV mutants resistant to various drugs has not been studied. To investigate this, we performed in vitro drug susceptibility assays using natural and artificial mutants that are associated with resistance to LMV, ADV, ETV or TDF. As a result, LMV-resistant mutants were not susceptible to BFV and ETV-resistant clones showed partial resistance against BFV as well. However, ADV-resistant mutants were highly sensitive to BFV. In case of tenofovir-resistant mutations, the HBV mutants harboring primary mutations to tenofovir resistance were susceptible to BFV. Therefore, our study revealed that BSV may serve as an alternative drug for patients with ADV-, ETV-, TDF- or TAF-resistance.

[1]  Ah Ram Lee,et al.  Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient , 2021, Biomedicines.

[2]  J. Song,et al.  Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B , 2021, Expert opinion on pharmacotherapy.

[3]  H. Mitsuya,et al.  Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations , 2021, Journal of virology.

[4]  Ah Ram Lee,et al.  Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes , 2021, International journal of molecular sciences.

[5]  D. J. Kim,et al.  Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial , 2021, Clinical and molecular hepatology.

[6]  D. J. Kim,et al.  Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial , 2020, The American journal of gastroenterology.

[7]  Ah Ram Lee,et al.  Entecavir‐resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[8]  J. Kao,et al.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy , 2020, Clinical Microbiology Reviews.

[9]  H. Mitsuya,et al.  Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine , 2020, Scientific Reports.

[10]  U. Lopatin.  Drugs in the Pipeline for HBV. , 2019, Clinics in liver disease.

[11]  S. Yoon,et al.  Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. , 2019, Journal of hepatology.

[12]  Ah Ram Lee,et al.  Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. , 2019, Journal of hepatology.

[13]  Sae-Hwan Lee,et al.  KASL clinical practice guidelines for management of chronic hepatitis B , 2019, Clinical and molecular hepatology.

[14]  D. J. Kim,et al.  Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  J. McKeating,et al.  Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. , 2018, Journal of hepatology.

[16]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[17]  S. Urban,et al.  Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles , 2018, Journal of Virology.

[18]  P. Roingeard,et al.  Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver , 2017, Gastroenterology.

[19]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[20]  F. Lu,et al.  Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B , 2016, Experimental and therapeutic medicine.

[21]  J. Kao,et al.  Hepatitis B virus: new therapeutic perspectives , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[22]  S. Rayner,et al.  Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment. , 2015, The Journal of general virology.

[23]  S. Chakrabarti,et al.  High Incidence of Lamivudine-Resistance-Associated Vaccine-Escape HBV Mutants among HIV-Coinfected Patients on Prolonged Antiretroviral Therapy , 2015, Antiviral therapy.

[24]  Eun-Sook Park,et al.  Molecular diagnosis and treatment of drug-resistant hepatitis B virus. , 2014, World journal of gastroenterology.

[25]  W. Choe,et al.  The Impact of the Hepatitis B Virus Polymerase rtA181T Mutation on Replication and Drug Resistance Is Potentially Affected by Overlapping Changes in Surface Gene , 2014, Journal of Virology.

[26]  M. Yuen,et al.  Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B , 2013, Gut.

[27]  Soo-Youn Lee,et al.  Pharmacokinetic comparison of the maleate and free base formulations of LB80380, a novel nucleotide analog, in healthy male volunteers. , 2012, International journal of clinical pharmacology and therapeutics.

[28]  H. Yim,et al.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B , 2012, Clinical and molecular hepatology.

[29]  B. Seong,et al.  Discovery and Development of Anti-HBV Agents and Their Resistance , 2010, Molecules.

[30]  M. Yuen,et al.  Antiviral activity and safety of LB80380 in hepatitis B e antigen–positive chronic hepatitis B patients with lamivudine‐resistant disease , 2010, Hepatology.

[31]  W. Choe,et al.  Identification and Characterization of Clevudine-Resistant Mutants of Hepatitis B Virus Isolated from Chronic Hepatitis B Patients , 2010, Journal of Virology.

[32]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[33]  I. Serra,et al.  Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. , 2009, Antiviral research.

[34]  M. Yuen,et al.  LB80380: a promising new drug for the treatment of chronic hepatitis B , 2008 .

[35]  Amie J Dirks Naylor,et al.  Mechanisms of Zidovudine-Induced Mitochondrial Toxicity and Myopathy , 2008, Pharmacology.

[36]  M. Yuen,et al.  LB80380: a promising new drug for the treatment of chronic hepatitis B. , 2008, Expert opinion on investigational drugs.

[37]  M. Yuen,et al.  Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.

[38]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[39]  M. Yuen,et al.  A Randomized Placebo-Controlled, Dose-Finding Study of Oral Lb80380 in Hbeag-Positive Patients with Chronic Hepatitis B , 2006, Antiviral therapy.

[40]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[41]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.